References
- Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125(Pt 4), 861–870 (2002).
- Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinson’s disease. Mov. Disord. 27(1), 54–60 (2012).
- Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord. 20(2), 190–199 (2005).
- Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov. Disord. 23(6), 837–844 (2008).
- Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov. Disord. 25(15), 2493–2500 (2010).
- O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov. Disord. 23(1), 101–106 (2008).
- Pathak A, Senard JM. Blood pressure disorders during Parkinson’s disease: epidemiology, pathophysiology and management. Expert Rev. Neurother. 6(8), 1173–1180 (2006).
- Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov. Disord. 26(3), 399–406 (2011).
- Seppi K, Weintraub D, Coelho M et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson’s disease. Mov. Disord. 26(Suppl. 3), S42–S80 (2011).
- Ross GW, Petrovitch H, Abbott RD et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann. Neurol. 63(2), 167–173 (2008).
- Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR. Pre-motor features of Parkinson’s disease: the Honolulu–Asia Aging Study experience. Parkinsonism Relat. Disord. 18(Suppl. 1), S199–S202 (2012).
- Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24(2), 197–211 (2003).
- Abbott RD, Petrovitch H, White LR et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57(3), 456–462 (2001).
- Abbott RD, Ross GW, Petrovitch H et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov. Disord. 22(11), 1581–1586 (2007).
- Iranzo A, Molinuevo JL, Santamaría J et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 5(7), 572–577 (2006).
- Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 72(15), 1296–1300 (2009).
- Berg D, Lang AE, Postuma RB et al. Changing the research criteria for the diagnosis of Parkinson’s disease: obstacles and opportunities. Lancet Neurol. doi:10.1016/S1474-4422(13)70047-4 (2013) (Epub ahead of print).
- Siderowf A, Lang AE. Premotor Parkinson’s disease: concepts and definitions. Mov. Disord. 27(5), 608–616 (2012).
- Iranzo A, Lomeña F, Stockner H et al.; Sleep Innsbruck Barcelona (SINBAR) group. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol. 9(11), 1070–1077 (2010).